Literature DB >> 2022742

Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.

A von Eckardstein1, H Holz, M Sandkamp, W Weng, H Funke, G Assmann.   

Abstract

Apolipoprotein C-III is a major protein constituent of triglyceride rich lipoproteins and HDL. It occurs in plasma in three isoforms differing by their sialic acid content. Apo C-III putatively inhibits lipolysis and the apo E mediated hepatic uptake of remnants from triglyceride rich particles. We identified a heterozygous carrier of an apolipoprotein C-III variant by the presence of additional bands after isoelectric focusing (IEF) of VLDL. Structural analysis of the variant protein by HPLC, time-of-flight secondary ion mass spectrometry, and automated gas phase sequencing revealed a lysine to glutamic acid replacement in position 58. The underlying A to G exchange was verified by direct sequencing subsequent to amplification by polymerase chain reaction of exon 4 of the apo C-III gene. Family studies revealed vertical transmission of this defect. The two variant carriers exhibited plasma concentrations of HDL cholesterol and apo A-I above the 95th percentiles of sex matched controls whereas the unaffected father and sister showed normal values. The plasma concentrations of apo C-III in the two variant carriers were decreased by 30-40% compared with those of the two unaffected family members and to random controls. Using two-dimensional immunoelectrophoresis as well as IEF and subsequent scanning densitometry, we found that the low serum concentration of apo C-III was a consequence of diminished concentrations of the variant apo C-III isoproteins in both VLDL (15% of normal) and HDL (25% of normal). Apo C-III(Lys58----Glu) heterozygotes possessed unusual HDL as demonstrated by nondenaturing gradient gel electrophoresis. They consisted mainly of HDL2b and contained a proportion of atypically large particles, enriched in apo E, with a Stokes diameter of 13-18 nm and resembling HDLc. In conclusion, heterozygosity for a structural apo C-III variant--apo C-III(Lys58----Glu)--was identified in two hyperalphalipoproteinemic subjects characterized by the presence of low plasma apo C-III concentrations and atypically large HDL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022742      PMCID: PMC295277          DOI: 10.1172/JCI115190

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

2.  Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum.

Authors:  A H Terpstra; C J Woodward; F J Sanchez-Muniz
Journal:  Anal Biochem       Date:  1981-02       Impact factor: 3.365

3.  An economical assay for HDL phosphatidyl choline.

Authors:  H Schriewer; G Jung; F Emke; G Assmann
Journal:  J Clin Chem Clin Biochem       Date:  1983-10

4.  Identification of apolipoproteins involved in the interaction of human high density lipoprotein3 with receptors on cultured cells.

Authors:  N H Fidge; P J Nestel
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

5.  Binding of apolipoprotein A-I and A-II after recombination with phospholipid vesicles to the high density lipoprotein receptor of luteinized rat ovary.

Authors:  J Hwang; K M Menon
Journal:  J Biol Chem       Date:  1985-05-10       Impact factor: 5.157

6.  Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance.

Authors:  C R Sharpe; A Sidoli; C S Shelley; M A Lucero; C C Shoulders; F E Baralle
Journal:  Nucleic Acids Res       Date:  1984-05-11       Impact factor: 16.971

7.  Isolation and sequence analysis of the human apolipoprotein CIII gene and the intergenic region between the apo AI and apo CIII genes.

Authors:  A A Protter; B Levy-Wilson; J Miller; G Bencen; T White; J J Seilhamer
Journal:  DNA       Date:  1984-12

8.  One-step screening method for the polymorphism of apolipoproteins A-I, A-II, and A-IV.

Authors:  H J Menzel; R G Kladetzky; G Assmann
Journal:  J Lipid Res       Date:  1982-08       Impact factor: 5.922

9.  Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease.

Authors:  R A Norum; J B Lakier; S Goldstein; A Angel; R B Goldberg; W D Block; D K Noffze; P J Dolphin; J Edelglass; D D Bogorad; P Alaupovic
Journal:  N Engl J Med       Date:  1982-06-24       Impact factor: 91.245

10.  [The enzymatic analysis of sphingomyelin in HDL (author's transl)].

Authors:  H Schriewer; H U Jabs; G Assmann
Journal:  J Clin Chem Clin Biochem       Date:  1982-05
View more
  19 in total

1.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

2.  Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels.

Authors:  J C Cohen; Z Wang; S M Grundy; M R Stoesz; R Guerra
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

3.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

4.  Uremia alters HDL composition and function.

Authors:  Michael Holzer; Ruth Birner-Gruenberger; Tatjana Stojakovic; Dalia El-Gamal; Veronika Binder; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2011-07-29       Impact factor: 10.121

5.  Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen.

Authors:  Wen Qin; Meenakshi Sundaram; Yuwei Wang; Hu Zhou; Shumei Zhong; Chia-Ching Chang; Sanjay Manhas; Erik F Yao; Robin J Parks; Pamela J McFie; Scot J Stone; Zhenghui G Jiang; Congrong Wang; Daniel Figeys; Weiping Jia; Zemin Yao
Journal:  J Biol Chem       Date:  2011-06-15       Impact factor: 5.157

6.  Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.

Authors:  Daniel B Larach; Marina Cuchel; Daniel J Rader
Journal:  Clin Lipidol       Date:  2013-12

7.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

8.  Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.

Authors:  A Inazu; X C Jiang; T Haraki; K Yagi; N Kamon; J Koizumi; H Mabuchi; R Takeda; K Takata; Y Moriyama
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Hu Zhou; Zhenghui G Jiang; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Daniel Figeys; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01-23       Impact factor: 5.922

10.  The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.

Authors:  Meenakshi Sundaram; Kaitlin R Curtis; Mohsen Amir Alipour; Nicholas D LeBlond; Kaitlyn D Margison; Rebecca A Yaworski; Robin J Parks; Adam D McIntyre; Robert A Hegele; Morgan D Fullerton; Zemin Yao
Journal:  J Lipid Res       Date:  2017-09-08       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.